Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...

Instil Bio, Inc. TIL shares dropped 25% to $63.50. The company announced the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in ...

NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.

NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...

NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...

As of 10:10 CEST. Market open. Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: ...

FALLS CHURCH, Va., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) will participate in the 12th Annual Morgan Stanley Laguna Conference on Thursday, September 12. Kathy ...

ATLANTA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc.(“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions ...